Tiziana Life Sciences Ltd
TLSA$153M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaLONDON, ENGLAND9 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Apr 30, 2026
6wMarket Overview
Stock performance and key metrics
TLSA News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Foralumab Nasal
Multiple System Atrophy
Foralumab
Secondary Progressive Multiple Sclerosis
Foralumab TZLS-401 100 µg
Non-Active Secondary Progressive Multiple Sclerosis
Milciclib maleate
Hepatocellular Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Foralumab Nasal | Phase 2 | Multiple System Atrophy | - | - |
Foralumab | Phase 2 | Secondary Progressive Multiple Sclerosis | - | - |
Foralumab TZLS-401 100 µg | Phase 2 | Non-Active Secondary Progressive Multiple Sclerosis | - | - |
Milciclib maleate | Phase 2 | Hepatocellular Carcinoma | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply